Publications
An Advance for Multiple Myeloma Patients
Conquest - Spring 2010
The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a Phase II clinical trial.
The updated data from the 17-site study focuses on patients with relapsed or resistant multiple myeloma who have received one to three prior therapies, but not the drug bortezomib, the original proteasome inhibitor.
Michael Wang, M.D.
- “These findings are truly an advance for patients with multiple myeloma,” says Michael Wang, M.D., associate professor in the Department of Lymphoma/Myeloma at
- MD Anderson and lead author on the study. “This is an incurable, challenging disease with devastating consequences. While new agents are extending life expectancies, they often have adverse side effects, including severe neuropathy. Carfilzomib is showing good response rates, with an improved side effects profile.”
Neuropathy is peripheral nerve pain or numbness that can become debilitating enough to halt treatment.
Reported in December 2009 at the 51st Annual Meeting of the American Society of Hematology.
Conquest - Spring 2010
Features
- Pathology: Investigating the Nature of Cancer
- What's in a Name? — New Logo Features Strike Through Cancer
- Found in Translation: SPORE Grants Turn Into Hope for Patients
- Transforming Cancer Care:
MD Anderson Launches Public Phase of Capital Campaign - Supportive Care Center Helps Manage Symptoms Throughout Cancer Journey
- Enlightened Choices: Individualized Options for Prostate Cancer Patients
- Moving Forward: Kevin Olson
Frontline
- Study Shifts Assessment of Certain Breast Cancer Patients
- An Advance for Multiple Myeloma Patients
- Team of Two Oncoproteins Crucial Step in Metastasis
- Blood Test May Detect Pancreatic Cancer
- Combined Therapies Show Promise in Small Cell Lung Cancer
- What Predicts Smoking Risk for Mexican-American Youth?
- Racial Disparities in Radiation Therapy for Early-Stage Breast Cancer